• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2018 - Product Image

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2018

  • ID: 1922038
  • September 2011
  • 93 pages
  • GlobalData

Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Cytomegalovirus (CMV) Infections market. The report identifies the key trends shaping and driving the global Cytomegalovirus (CMV) Infections market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cytomegalovirus (CMV) Infections sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Cytomegalovirus (CMV) Infections market. Its scope includes -
- Annualized seven key markets READ MORE >

Note: Product cover images may vary from those shown

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 CMV Infections - Introduction
2.1 Overview
2.2 Etiology and Pathophysiology
2.3 Signs and Symptoms
2.4 Epidemiology
2.5 Diagnosis
2.6 Treatment
2.7 Pipeline Report Guidance
3 CMV Infections - Market Characterization
3.1 CMV Infections Market Size (2005-2010) - Global
3.2 CMV Infections Market Forecast (2010-2018) - Global
3.3 CMV Infections Market Size (2005-2010) - The US
3.4 CMV Infections Market Forecast (2010-2018) - The US
3.5 CMV Infections Market Size (2005-2010) - France
3.6 CMV Infections Market Forecast (2010-2018) - France
3.7 CMV Infections Market Size (2005-2010) - Germany
3.8 CMV Infections Market Forecast (2010-2018) - Germany
3.9 CMV Infections Market Size (2005-2010) - Italy
3.10 CMV Infections Market Forecast (2010-2018) - Italy
3.11 CMV Infections Market Size (2005-2010) - Spain
3.12 CMV Infections Market Forecast (2010-2018) - Spain
3.13 CMV Infections Market Size (2005-2010) - The UK
3.14 CMV Infections Market Forecast (2010-2018) - The UK
3.15 CMV Infections Market Size (2005-2010) - Japan
3.16 CMV Infections Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the CMV Infections Market
3.17.1 Drivers for the CMV Infections Market
3.17.2 Barriers for the CMV Infections Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 CMV Infections Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Product in the CMV Infections Market
4.3.1 Ganciclovir
4.3.2 Valcyte (Valganciclovir )
4.3.3 Cidofovir
4.3.4 Foscarnet
4.3.5 CMV-IGIV
4.4 Key Takeaway
5 CMV Infections - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 CMV Infections - Pipeline Analysis by Phase of Development
5.3.1 CMV Infections - Phase III Clinical Pipeline
5.3.2 CMV Infections - Phase II Clinical Pipeline
5.3.3 CMV Infections - Phase I Pipeline
5.3.4 CMV Infections - Pre-clinical Pipeline
5.3.5 CMV Infections - Discovery Pipeline
5.4 CMV Infections - Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 CMV Infection - Most Promising Drugs under Clinical Development
5.7 Most Promising Drug Profiles
5.7.1 TransVax
5.7.2 Adoptive Cellular Therapy (CMV Specific T-Cells)
5.8 Key Takeaway
6 CMV Infections - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 & Japan)
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials by Sponsors
6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials
7 CMV Infections Market - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 CMV Infections Market - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 F.Hoffmann-La Roche Ltd. (Roche)
8.2.2 Vical Incorporated (Vical)
8.2.3 Cell Medica Limited (Cell Medica)
8.2.4 Other Companies in the CMV Infections Market
8.3 Key Takeaway
9 CMV Infections - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

1.1 List of Tables
Table 1: CMV Assay Sensitivities and Predictive Values
Table 2: CMV Infections Market, Global, Revenue ($m), 2005-2010
Table 3: CMV Infections Market, Global, Revenue ($m), 2010-2018
Table 4: CMV Infections Market, The US, Revenue ($m), 2005-2010
Table 5: CMV Infections Market, The US, Forecast ($m), 2010-2018
Table 6: CMV Infections Market, France, Revenue ($m), 2005-2010
Table 7: CMV Infections Market, France, Revenue ($m), 2010-2018
Table 8: CMV Infections Market, Germany, Revenue ($m), 2005-2010
Table 9: CMV Infections Market, Germany, Forecasts ($m), 2010-2018
Table 10: CMV Infections Market, Italy, Revenue ($m), 2005-2010
Table 11: CMV Infections Market, Italy, Revenue ($m), 2010-2018
Table 12: CMV Infections Market, Spain, Revenue ($m), 2005-2010
Table 13: CMV Infections Market, Spain, Forecasts ($m), 2010-2018
Table 14: CMV Infections Market, the UK, Revenue ($m), 2005-2010
Table 15: CMV Infections Market, The UK, Forecasts ($m), 2010-2018
Table 16: CMV Infections Market, Japan, Revenue ($m), 2005-2010
Table 17: CMV Infections Market, Japan, Forecasts ($m), 2010-2018
Table 18: Valcyte Efficacy details in CMV prophylaxis
Table 19: Efficacy Details of Valganciclovir in the Trials
Table 20: Adverse Events (in =5% of patients) Associated with Maintenance Treatment with Valcyte
Table 21: Serious Clinical Adverse Events in >5% of Patients
Table 22: CMV Infections Market, Phase III Pipeline, 2011
Table 23: CMV Infections Market, Phase II Pipeline, 2011
Table 24 CMV Infections Market, Phase I Pipeline, 2011
Table 25: CMV Infections Market, Pre-clinical Pipeline, 2011
Table 26: CMV Infections Market, Discovery Pipeline, 2011
Table 27: CMV Infections Market, Global, Most Promising Drugs Under Clinical Development, 2011
Table 28: Treatment Endpoints in a Phase II Trial of TransVax
Table 29: CMV Infections, Global, Clinical Trials, 2011
Table 30: CMV Infections, Global, Clinical Trials by Phase, 2011
Table 31: CMV Infections, Global, Clinical Trials by Status of Development, 2011
Table 32: CMV Infections, Global, Prominent Sponsors, 2011
Table 33: CMV Infections, Global, Top 10 Companies by Phase, 2011
Table 34: Roche Pipeline Products
Table 35: Vical Pipeline Products
Table 36: CMV Infections Market-Other Future Players
Table 37: CMV Infections, Global, Deals, 2010

1.2 List of Figures
Figure 1: CMV Infection Lifecycle
Figure 2: CMV Infections - Prophylaxis Algorithm
Figure 3: CMV Infections Prophylactic Market, Global, Revenue ($m), 2005-2010
Figure 4: CMV Infections Therapeutic Market, Global, Revenue ($m), 2005-2010
Figure 5: CMV Infections Prophylactic Market, Global, Revenue ($m), 2010-2018
Figure 6: CMV Infections Therapeutic Market, Global, Revenue ($m), 2010-2018
Figure 7: CMV Infections Prophylactic Market, The US, Revenue ($m), 2005-2010
Figure 8: CMV Infections Therapeutic Market, The US, Revenue ($m), 2005-2010
Figure 9: CMV Infections Prophylactic Market, The US, Forecast ($m), 2010-2018
Figure 10: CMV Infections Therapeutic Market, The US, Forecast ($m), 2010-2018
Figure 11: CMV Infections Prophylactic Market, France, Revenue ($m), 2005-2010
Figure 12: CMV Infections Therapeutic Market, France, Revenue ($m), 2005-2010
Figure 13: CMV Infections Prophylactic Market, France, Revenue ($m), 2010-2018
Figure 14: CMV Infections Therapeutic Market, France, Revenue ($m), 2010-2018
Figure 15: CMV Infections Prophylactic Market, Germany, Revenue ($m), 2005-2010
Figure 16: CMV Infections Therapeutic Market, Germany, Revenue ($m), 2005-2010
Figure 17: CMV Infections Prophylactic Market, Germany, Forecast ($m), 2010-2018
Figure 18: CMV Infections Therapeutic Market, Germany, Forecast ($m), 2010-2018
Figure 19: CMV Infections Prophylactic Market, Italy, Revenue ($m), 2005-2010
Figure 20: CMV Infections Therapeutic Market, Italy, Revenue ($m), 2005-2010
Figure 21: CMV Infections Prophylactic Market, Italy, Forecast ($m), 2010-2018
Figure 22: CMV Infections Therapeutic Market, Italy, Forecast ($m), 2010-2018
Figure 23: CMV Infections Prophylactic Market, Spain, Revenue ($m), 2005-2010
Figure 24: CMV Infections Therapeutic Market, Spain, Revenue ($m), 2005-2010
Figure 25: CMV Infections Prophylactic Market, Spain, Forecast ($m), 2010-2018
Figure 26: CMV Infections Therapeutic Market, Spain, Forecast ($m), 2010-2018
Figure 27: CMV Infections Prophylactic Market, the UK, Revenue ($m), 2005-2010
Figure 28: CMV Infections Therapeutic Market, the UK, Revenue ($m), 2005-2010
Figure 29: CMV Prophylactic Market, The UK, Forecast ($m), 2010-2018
Figure 30: CMV Therapeutic Market, The UK, Forecast ($m), 2010-2018
Figure 31: CMV Infections Prophylactic Market, Japan, Revenue ($m), 2005-2010
Figure 32: CMV Infections Therapeutic Market, Japan, Revenue ($m), 2005-2010
Figure 33: CMV Infections Prophylactic Market, Japan, Forecast ($m), 2010-2018
Figure 34: CMV Infections Therapeutic Market, Japan, Forecast ($m), 2010-2018
Figure 35: Opportunity and Unmet Need in the CMV Infections (Prophylactic) Market
Figure 36: Opportunity and Unmet Need in the CMV Infections (Therapeutic) Market
Figure 37: CMV Infections-Strategic Competitor Assessment, 2011 (Prophylactic)
Figure 38: CMV Infections-Strategic Competitor Assessment, 2011 (Therapeutic)
Figure 39: CMV Infections Market, Clinical Pipeline by Mechanism of Action (%), 2011
Figure 40: CMV Infections Market - Clinical Pipeline by Phase of Development (%), 2011
Figure 41: Technology Trends Analytics Framework, 2011
Figure 42: Technology Trends Analytics Frame Work - Description, 2011
Figure 43: CMV Infections, Global, Clinical Trials by Country, 2011
Figure 44: CMV Infections, Global, Clinical Trials by Phase (%), 2011
Figure 45: CMV Infections, Global, Clinical Trials by Status of Development (%), 2011
Figure 46: CMV Infections, Global, Overall Sponsors (%), 2011
Figure 47: CMV Infections, Global, Prominent Sponsors (%), 2011
Figure 48: CMV Infections, Global, Top 10 Companies by Phase, 2011
Figure 49: CMV Infections Market, Drivers and Barriers, 2011
Figure 50: Implications for Future Market Competition in the CMV Infections Market, 2011
Figure 51: CMV Infections Market, Clinical Pipeline by Company, 2011
Figure 52: Market Forecasting Model

Note: Product cover images may vary from those shown

Industry analysis specialist, GlobalData, has released its new report, “Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global CMV infections market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global CMV infections market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global CMV infections sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The CMV Infections Market is Forecast to Show High Growth until 2018

GlobalData estimated the global CMV infections market to be $602.1m in 2010. It is forecast to grow at a CAGR (Compound Annual Growth Rate) of 6.5% for the next eight years to reach $996.6m by 2018. This high growth in the market is primarily driven by the growth in the CMV prophylactic market.

The CMV prophylactic market was estimated around $404.1m in 2010 and is forecast to grow at a CAGR of 8.5% to reach $778.4m in 2018. The prophylactic market will witness the launch of two new products in the forecast period, TransVax, the first vaccine for CMV prevention, in the US and Europe and adoptive cellular therapy, a CMV-specific T-cell infusion, in the Europe. TransVax, being the first CMV prophylactic vaccine will have a significant impact on the market.

The CMV therapeutic market was estimated to be $198.0m in 2010 and is forecast to grow at a CAGR of 1.2% to reach $218.2m in 2018. The therapeutic market will not have any significant launch in the forecast period except the launch of an already approved product, Cytotect (CMV hyperimmunoglobulin). In Europe, it is launched for CMV prophylaxis in transplant recipients and is currently in Phase III for congenital CMV.

The growth in Human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) patients, bone marrow transplants and solid organ transplants also contributes to the growth of the market.

The currently used treatment options for CMV infections are a mix of patented as well as generic drugs. Valcyte (valganciclovir) is the only patented drug while ganciclovir, foscarnet and cidofovir are generics. Cidofovir is off-patent in the US; however it will lose its patent in Europe in 2012. Cytogam (CMV Immune Globulin Intravenous (Human)) is an old biologic available since 1992. Valcyte is the patented drug which will undergo genericization in US and Europe in 2013 and 2015 respectively.

The Valcyte, a patented drug and ganciclovir are approved for both prophylaxis and therapeutics; cidofovir and foscarnet are for therapeutics alone and CMV Immune Globulin Intravenous (Human) for prophylaxis alone.

The expected launch of biologics such as vaccine and CMV-specific T-cell products during the forecast period will drive the market growth due to their novelty and premium price.

CMV Infections Market, Global, Revenue and Market Forecast ($m), 2005-2018

Sources: GlobalData, GlobalData Epidemiology-based Market Forecasting Model, United Network for Organ Sharing (UNOS), National Health Service Blood and Transplant (NHSBT) statistics, International Figures on organ donation and transplantation - By Council of Europe (Transplant Newsletter), CDC (Centers for Disease Control and Prevention), A. Ludwig, H.Hengel, “Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe”, Eurosurveillance; Vol . 14. Issue 9. 5 March 2009, Key Opinion Leader (KOL) Interviews

Note: Product cover images may vary from those shown

F.Hoffmann-La Roche Ltd. (Roche)
Vical Incorporated (Vical)
Cell Medica Limited (Cell Medica)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos